glp-1 and inflammation Drugs: For Multiple Chronic Conditions GLP-1 RAs may lead to
Description
Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, et al
What makes this drug unique is that it is the first in this new class of medications
Some studies involving healthy subjects reported that endogenous GIP contributes to up to 25% of the suppression of bone resorption after a meal, while it found that endogenous GLP-1 has no impact on postprandial bone homeostasis [53, 54]
For type 2 diabetes, NICE recommends continuing GLP-1 therapy only if HbA1c falls by 11 mmol/mol AND body weight reduces by 3% at 6 months
U., Sprengart, M
mean eGFR was 65.0 (s.d
